Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.

ABSTRACT:

Background

Cytokine-release syndrome (CRS) is a common toxicity of chimeric antigen receptor (CAR) T cells. CRS is often treated with corticosteroids such as dexamethasone. Dexamethasone is also used to treat multiple myeloma. To model CRS after CAR T-cell treatment of multiple myeloma (MM), three cell types are required: monocyte-lineage cells, CAR T cells, and MM cells. Some cytokines important in CRS, including interleukin (IL)-6, are released mainly by monocyte-lineage cells.

Methods

We added cells of an acute monocytic leukemia cell line (THP-1) to co-cultures of anti-B-cell maturation antigen (BCMA) CAR T cells (CAR-BCMA) and BCMA⁺ target cells. Addition of THP-1 cells to the co-cultures led to increased levels of IL-6 and monocyte chemoattractant protein-1

SUBMITTER: Amatya C 

PROVIDER: S-EPMC12918699 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature